Cell Death and Disease · 2024 · 12 citations · 59 references
Life SciencesMolecular BiologyOncologyCell SignalingGene ExpressionMolecular OncologyCancer Cell SignalingCancer MetabolismNuclear Pore ComplexesNuclear ReceptorsNuclear TransportNuclear-cytoplasmic TransportNuclear Pore Complex TransportPeroxisome Proliferator Receptor SignalingPeroxisome Proliferator-activated Receptor Gamma RegulationPeroxisome Proliferator-activated Receptor SignalingPeroxisome Proliferator-activated ReceptorsTransmembrane ProteinsTumor Cell MetabolismTumor Metabolism
Manipulation of the subcellular localization of transcription factors by preventing their shuttling via the nuclear pore complex (NPC) emerges as a novel therapeutic strategy against cancer. One transmembrane component of the NPC is POM121, encoded by a tandem gene locus POM121A/C on chromosome 7. Overexpression of POM121 is associated with metabolic diseases (e.g., diabetes) and unfavorable clinical outcome in patients with colorectal cancer (CRC). Peroxisome proliferator-activated receptor-gamma (PPARγ) is a transcription factor with anti-diabetic and anti-tumoral efficacy. It is inhibited by export from the nucleus to the cytosol via the RAS-RAF-MEK1/2-ERK1/2 signaling pathway, a major oncogenic driver of CRC. We therefore hypothesized that POM121 participates in the transport of PPARγ across the NPC to regulate its transcriptional activity on genes involved in metabolic and tumor control. We found that POM121A/C mRNA was enriched and POM121 protein co-expressed with PPARγ in tissues from CRC patients conferring poor prognosis. Its interactome was predicted to include proteins responsible for tumor metabolism and immunity, and in-silico modeling provided insights into potential 3D structures of POM121. A peptide region downstream of the nuclear localization sequence (NLS) of POM121 was identified as a cytoplasmic interactor of PPARγ. POM121 positivity correlated with the cytoplasmic localization of PPARγ in patients with KRAS mutant CRC. In contrast, POM121A/C silencing by CRISPR/Cas9 sgRNA or siRNA enforced nuclear accumulation of PPARγ and activated PPARγ target genes promoting lipid metabolism and cell cycle arrest resulting in reduced proliferation of human CRC cells. Our data suggest the POM121-PPARγ axis as a potential drugable target in CRC.
59
Damian Szklarczyk, Annika L. Gable, David Lyon et al. · Nucleic Acids Research · 2018 · 19.2K citations · Full text
Ethan Cerami, Jianjiong Gao, Uğur Doğrusöz et al. · Cancer Discovery · 2012 · 18.4K citations · Full text
Medicine, Bioinformatics, Oncology +15
The Phyre2 web portal for protein modeling, prediction and analysis
Lawrence A. Kelley, Stefans Mezulis, Christopher M. Yates et al. · Nature Protocols · 2015 · 10.2K citations · Full text
The consensus molecular subtypes of colorectal cancer
Justin Guinney, Rodrigo Dienstmann, Xin Wang et al. · Nature Medicine · 2015 · 5.3K citations · Full text